Edwards Lifesciences Corporation logo

Edwards Lifesciences Corporation (EWL)

Market Open
4 Dec, 20:00
XMUN XMUN
72. 27
-0.87
-1.19%
- Market Cap
32.12 P/E Ratio
0% Div Yield
0 Volume
2.51 Eps
73.14
Previous Close
Day Range
72.27 72.27
Year Range
59.65 74.74
Want to track EWL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 61 days

Summary

EWL trading today lower at €72.27, a decrease of 1.19% from yesterday's close, completing a monthly decrease of -3.19% or €2.38. Over the past 12 months, EWL stock gained 0.88%.
EWL is not paying dividends to its shareholders.
The last earnings report, released on Oct 30, 2025, exceeded the consensus estimates by 0.08%. On average, the company has fell short of earnings expectations by -0.16%, based on the last three reports. The next scheduled earnings report is due on Feb 04, 2026.
Edwards Lifesciences Corporation has completed 3 stock splits, with the recent split occurring on Jun 01, 2020.
The company's stock is traded on 10 different exchanges and in various currencies, with the primary listing on NYSE (USD).

EWL Chart

Is the Options Market Predicting a Spike in Edwards Lifesciences Stock?

Is the Options Market Predicting a Spike in Edwards Lifesciences Stock?

Investors need to pay close attention to EW stock based on the movements in the options market lately.

Zacks | 4 weeks ago
Edwards Lifesciences Corporation (EW) Q3 2025 Earnings Call Transcript

Edwards Lifesciences Corporation (EW) Q3 2025 Earnings Call Transcript

Edwards Lifesciences Corporation ( EW ) Q3 2025 Earnings Call October 30, 2025 5:00 PM EDT Company Participants Mark Wilterding - Vice President of Investor Relations Bernard Zovighian - CEO & Director Scott Ullem - Corporate VP & CFO Daniel Lippis - Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) Daveen Chopra - Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies Conference Call Participants Travis Steed - BofA Securities, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Matthew Taylor - Jefferies LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Presentation Operator Greetings, and welcome to the Edwards Lifesciences' Third Quarter 2025 Conference Call. [Operator Instructions] Please note, this conference is being recorded.

Seekingalpha | 1 month ago
Edwards Lifesciences (EW) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Edwards Lifesciences (EW) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 1 month ago

Edwards Lifesciences Corporation (EWL) FAQ

What is the stock price today?

The current price is €72.27.

On which exchange is it traded?

Edwards Lifesciences Corporation is listed on NYSE.

What is its stock symbol?

The ticker symbol is EWL.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.61.

When is the next earnings date?

The next earnings report will release on Feb 04, 2026.

Has Edwards Lifesciences Corporation ever had a stock split?

Edwards Lifesciences Corporation had 3 splits and the recent split was on Jun 01, 2020.

Edwards Lifesciences Corporation Profile

- Industry
- Sector
Bernard J. Zovighian CEO
XMUN Exchange
US28176E1082 ISIN
US Country
15,800 Employees
- Last Dividend
1 Jun 2020 Last Split
27 Mar 2000 IPO Date

Overview

Edwards Lifesciences Corporation specializes in providing advanced medical technologies tailored to diagnose and treat structural heart diseases and conditions requiring critical care monitoring. The company has a global footprint, offering its state-of-the-art products and solutions across the United States, Europe, Japan, and other international markets. Founded in 1958, Edwards Lifesciences has its headquarters in Irvine, California, and leverages both a direct sales force and a network of independent distributors to reach its market.

Products and Services

  • Transcatheter Heart Valve Replacement Products:

    Under the Edwards SAPIEN family, these products offer minimally invasive options for replacing aortic heart valves, enabling significant improvements in patient outcomes and recovery times.

  • Transcatheter Heart Valve Repair and Replacement Products:

    Targeting mitral and tricuspid valve diseases, products under the PASCAL PRECISION and Cardioband names offer advanced solutions for valve repair and replacement, supporting heart function restoration.

  • Surgical Structural Heart Solutions:

    Edwards provides various surgical solutions including the INSPIRIS aortic surgical valve and the INSPIRIS RESILLA valve, featuring RESILIA tissue and VFit technology for enhanced durability. The KONECT RESILIA and MITRIS RESILIA valve products support complex procedures with pre-assembled tissue valves and innovative designs for better patient outcomes.

  • Critical Care Solutions:

    The company's critical care portfolio includes hemodynamic monitoring systems such as FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight, designed to measure heart function and fluid status in surgical and ICU settings accurately. The HemoSphere monitoring platform visually displays critical physiological information, and the Acumen Hypotension Prediction Index software utilizes advanced algorithms to predict and alert clinicians of potential dangerous drops in blood pressure.

Contact Information

Address: One Edwards Way
Phone: 949 250 2500